Abbott's ABSORB Bioresorbable Vascular Scaffold Honored with Wall Street Journal Technology Innovation Award

Award Recognizes Advanced Therapy for Coronary Artery Disease that Treats Blocked Vessel, then Dissolves

18-Oct-2011 - USA

Abbott announced that the investigational ABSORB™ bioresorbable vascular scaffold (BVS) has been recognized as the winner of the medical devices category in the 2011 Wall Street Journal Technology Innovation Awards. ABSORB is an implantable device that restores blood flow by opening a blocked artery and providing support to the vessel until the device dissolves. Once in place, ABSORB dissolves in approximately two years, leaving patients with a treated vessel free of a permanent metallic implant.
The first drug eluting device of its kind for coronary artery disease, ABSORB is made of polylactide, a proven biocompatible material that is commonly used in medical implants such as dissolvable sutures. Because a permanent metallic implant is not left behind, naturally occurring vessel functions may be restored, which is one of the features that make this device a significant innovation for patients in the evaluation and treatment of coronary artery disease.
"ABSORB represents the best in scientific innovation, as it has the potential to change the way physicians practice medicine and improve outcomes for their patients," said Robert B. Hance, senior vice president, vascular, Abbott. "We are pleased that this innovation, which has been developed in the U.S. over nearly a decade, has the prospect of advancing patient care around the globe. Abbott is honored to receive this prestigious award."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances